https://shiftbioscience.com/
We have identified small molecule ‘Shift’ drugs that combat diverse age-accumulated mitochondrial genome damage
We will minimize costs and timescales for clinical development of Shift drugs by first targeting the orphan disease MELAS, which is caused by inherited mitochondrial dysfunction. A clinical trial for MELAS requires fewer participants due to the rarity of the disease and the larger degree of unmet clinical need. Drug efficacy is easier to demonstrate due to clearer biological/clinical endpoints.